Dendritic cell vaccination.
There has been a surge of interest in the use of dendritic cell (DC) vaccination as cellular immunotherapy for numerous cancers. Despite some encouraging results, this therapeutic modality is far from being considered as a therapy for cancer. This review will first discuss preclinical DC vaccination in murine models of cancer, with an emphasis on comparative studies investigating different methods of antigen priming. We will then comment on the various murine DC subsets and how these relate to human DC preparations used for clinical studies. Finally, the methodology used to generate human DCs and some recent clinical trials in several cancers are reviewed.
Bio-Organic and Medicinal Chemistry Laboratory, Burnet Institute at Austin, Studley Rd, Heidelberg, 3084, Victoria, Australia. oproudfoot@burnet.edu.au
Owen
O
Proudfoot
Dodie
D
Pouniotis
Kuo-Ching
KC
Sheng
Bruce E
BE
Loveland
Geoffrey A
GA
Pietersz
D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis; D001943:Breast Neoplasms / Q000628:therapy; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005312:Fetal Blood / Q000166:cytology; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D007938:Leukemia / Q000628:therapy; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D008297:Male; D008545:Melanoma / Q000628:therapy; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000628:therapy; D014162:Transfection; D014611:Vaccination
D018952:Antigens, CD34; D018950:Lipopolysaccharide Receptors